Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine
Effectiveness of a Bivalent, Killed Whole-cell Based Oral Cholera Vaccine(Shanchol®) Delivered Through Community-based Mass Vaccination Campaign in a High-risk Population in India: Matched Case-control Studies
Various field studies has found that the modified , bivalent, whole cell - based oral cholera vaccine (OCV) to be safe, immunogenic and effective with protective efficacy of 67 % in earlier clinical trials. However, the effectiveness of the vaccine in "real" life situation using the public health system is unknown. It is critical to follow up in the same population, where pilot introduction of OCV was introduced and evaluate vaccine proactive effectiveness at individual as well as at population level. The follow - up and determination of effectiveness of mass OCV vaccination was requested by State Government.
The overall goal of this study is to evaluate the protective effectiveness of one or two doses of modified, bivalent, killed whole cell based OCV, given at least 14 days apart, when delivered through community - based mass vaccination campaign using existing public health infrastructure in a high - risk population in Satyabadi block of Puri district, Orissa, India. This study has following objectives Primary objectives: * To evaluate the individual level protective effectiveness of one or two doses of OCV against culture confirmed cholera episodes, severe enough to seek a formal health care. Secondary objectives: - To evaluate population - level effectiveness (herd effects)of OCV delivered through a community based mass vaccination when the vaccine is delivered to more than half of population at risk. - To determine inverse correlation between vaccine coverage and cholera incidence among diverse geographical clusters.
Vaccine protective effectiveness at individual level
Population level effectiveness (herd effect)
Study Arms / Comparison Groups
Cholera cases group
Description: "Any diarrheal cases or suspected cholera cases from study area, whose stool specimen collected in study health center and examined in reference laboratory, reveals V. cholerae serotype O1/O139 is defined as cholera case"
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Primary Completion Date
Inclusion criteria for cases of the main case-control study are as follows: - Giving verbal informed consent/assent, or in the case of minors, a parent or guardian give informed consent to participate in the study - Living in the study area since the start of the mass vaccination - Submitted a faecal specimen - Whose residence could be located - Whose stool specimens yield V. cholera O1 or O139 - Belonging to study population through census database Exclusion criteria: - Not giving verbal informed consent/assent, or in the case of minors, a parent or guardian does not give informed consent to participate in the study - Not living in the study area since the start of the mass vaccination - No faecal specimen - Whose residence could not be located - Whose stool specimens does not yield V. cholera O1 or O139 - Not belonging to study population through census database
1 Year - N/A
Accepts Healthy Volunteers
Shantanu K Kar, MD, +822 - 8811 442, [email protected]
International Vaccine Institute
Department of Health and Family Welfare, Orissa
Shantanu K Kar, MD, Principal Investigator, Director, Regional Medical Research Center, Bhubanewar, Orissa, India